Emerging issues with bisphosphonates.
Bisphosphonates are the most commonly used agents in the management of metabolic bones diseases. Despite their established therapeutic value, a number of points of uncertainty remain, particularly in connection with their optimal long-term use. It is likely that definitive clinical trial data will not become available to resolve these questions, so careful clinical observation and caution are needed in patients who require treatment over periods of more than 10 years.
Reid
Ian R
IR
Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand. ireid@auckland.ac.nz
D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control; D006801:Humans; D010001:Osteitis Deformans / Q000188:drug therapy; D010024:Osteoporosis / Q000150:complications
D050071:Bone Density Conservation Agents; D004164:Diphosphonates